Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05ZDD
|
|||
| Former ID |
DIB007079
|
|||
| Drug Name |
Recombinant human cartilage-derived retinoic acid-sensitive protein depot
|
|||
| Synonyms |
ST-03; MIA protein (osteochrondral defects),Scil; Melanoma inhibitory activity (osteochrondral defects), Scil; Recombinant human cartilage-derived retinoic acid-sensitive protein depot (osteochrondral defects); RhCD-RAP (osteochrondral defects), Pfizer; RhCD-RAP (osteochrondral defects), Scil; Recombinant human cartilage-derived retinoic acid-sensitive protein depot (osteochrondral defects), Pfizer; Recombinant human cartilage-derived retinoic acid-sensitive protein depot (osteochrondral defects), Scil
Click to Show/Hide
|
|||
| Indication | Articular cartilage disorder [ICD-11: FA34.Y] | Phase 2/3 | [1] | |
| Company |
Scil Technology GmbH
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00450203) Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.